By Bernadette Toner

Having wrapped up two mergers in a little over a year, Accelrys views additional acquisitions as a key part of its future growth strategy and is on the hunt for viable candidates, company officials said this week.

In a call to discuss the company's third-quarter financial results, Accelrys CEO Max Carnecchia said the firm views acquisitions as one component of a "three-pronged" growth strategy that also includes organic product development and an expanded partner network.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: Icelandic genome sequences, approach to increase CRISPR efficiency, and more.

Testing showing "genetic incompatibilities" have led thousands of couples in Saudi Arabia to call off their weddings, the BBC reports.

Decode Genetics' ability to tell Icelanders, even ones the company hasn't sequenced, about their disease risk brings up ethical questions.

Genetic analysis of Britain's King Richard III and modern descendants of his relatives indicate breaks in the male line.